|Systematic (IUPAC) name|
|(what is this?)|
O-823 is a drug which is a cannabinoid derivative that is used in scientific research. It is described as a mixed agonist/antagonist at the cannabinoid receptor CB1, meaning that it acts as an antagonist when co-administered alongside a more potent CB1 agonist, but exhibits weak partial agonist effects when administered by itself.
- Pertwee RG, Fernando SR, Griffin G, Ryan W, Razdan RK, Compton DR, Martin BR. Agonist-antagonist characterization of 6'-cyanohex-2'-yne-delta 8-tetrahydrocannabinol in two isolated tissue preparations. European Journal of Pharmacology. 1996 Nov 14;315(2):195-201. PMID 8960884
- Griffin G, Wray EJ, Rorrer WK, Crocker PJ, Ryan WJ, Saha B, Razdan RK, Martin BR, Abood ME. An investigation into the structural determinants of cannabinoid receptor ligand efficacy. British Journal of Pharmacology. 1999 Apr;126(7):1575-84. doi:10.1038/sj.bjp.0702469 PMID 10323589
- Griffin G, Wray EJ, Martin BR, Abood ME. Cannabinoid agonists and antagonists discriminated by receptor binding in rat cerebellum. British Journal of Pharmacology. 1999 Oct;128(3):684-8. doi:10.1038/sj.bjp.0702806 PMID 10516649
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|